IntraBio Inc   Report issue

For profit Phase 3
Founded: Oxford United Kingdom (2015)

Organization Overview

First Clinical Trial
2019
NCT03759665
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

IntraBio Inc

Active Ingredients

Drugs in Phase 3 Trials (1)

n-acetylleucine (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Aphasia, Primary Progressive (Phase 2)

Ataxia (Phase 2)

Ataxia Telangiectasia (Phase 2)

Cerebellar Ataxia (Phase 2)

Frontotemporal Dementia (Phase 2)

Gangliosidoses (Phase 2)

Gangliosidoses, GM2 (Phase 2)

Niemann-Pick Diseases (Phase 2)

Niemann-Pick Disease, Type A (Phase 2)

Niemann-Pick Disease, Type C (Phase 2)

Pick Disease of the Brain (Phase 2)

Sandhoff Disease (Phase 2)

Tay-Sachs Disease (Phase 2)

Telangiectasis (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 1